'Brain Hemorrhage Diagnosis Support' Coreline 'AIVIEW NeuroCAD', Hospital Non-Covered Service Billing Begins

Medical AI company Coreline Soft's brain hemorrhage diagnosis assistance solution, AVIEW NeuroCAD, is now eligible for non-reimbursable billing.

Coreline Soft announced on the 18th that on the 16th, the Korea Health Industry Development Institute (NECA) completed the 'Notification of Use of Innovative Medical Technology (Clinical Practice) Result' for AVIEW NeuroCAD. Accordingly, AVIEW NeuroCAD can now be applied to analyze brain computed tomography (CT) scans of patients visiting the emergency rooms at 16 hospitals that have introduced AVIEW NeuroCAD, including Inje University Ilsan Paik Hospital, Gumi CHA Hospital, Sejong Chungnam National University Hospital, and Samyook Busan Hospital. Additionally, Coreline Soft can now charge hospitals a certain fee per analysis case.

A representative from Coreline Soft said, “From the existing business model where hospitals purchase the solution, it is significant in business terms that we can expand by applying a Software as a Service (SaaS) model based on usage volume targeting emergency rooms, which increases revenue.”

AVIEW NeuroCAD is brain hemorrhage imaging detection and diagnosis assistance software that supports reading images and making diagnosis and treatment decisions within a limited time based on patient CT images.

It features ▲sorting patient groups from images with heavy hemorrhage ▲providing prioritized lesion information according to hemorrhage volume ▲previewing suspected brain hemorrhage areas. It also allows comparison between 2D and 3D images and integrates with medical institutions’ Picture Archiving and Communication Systems (PACS). Recognized for its technological innovation and potential to create new markets, it was selected as an innovative medical technology through the integrated review evaluation by the Ministry of Food and Drug Safety and the Ministry of Health and Welfare last year, enabling its use in medical settings under selective reimbursement or non-reimbursable status.

Professor Choi Seungpil, head of the Emergency Medicine Center at Gumi CHA Hospital, which introduced the product, said, “Cerebrovascular diseases are called so-called golden time diseases, as recovery becomes difficult or death may occur if a certain amount of time passes, so we introduced AVIEW NeuroCAD for rapid diagnosis and treatment,” adding, “Based on this non-reimbursable billing, we will do our best to provide high-quality medical services to more patients.”